Cargando…

EMA-FDA Parallel Scientific Advice: Optimizing Development of Medicines in the Global Age

As medicines development continues towards a globalized approach, both the pharmaceutical industry and regulatory agencies increasingly seek opportunities to proactively engage early in product development. The parallel scientific advice program shared by the European Medicines Agency (EMA) and the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thor, Shannon, Vetter, Thorsten, Marcal, Anabela, Kweder, Sandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9985489/ https://www.ncbi.nlm.nih.gov/pubmed/36871110 http://dx.doi.org/10.1007/s43441-023-00501-9

Ejemplares similares

Considering Global Development? Insights from Applications for FDA Breakthrough Therapy and EMA PRIME Designations
por: Hanaizi, Zahra, et al.
Publicado: (2022)

A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014–2016: Concordance, Discordance, and Why
por: Kashoki, Mwango, et al.
Publicado: (2019)

The Added Value of Patient Engagement in Early Dialogue at EMA: Scientific Advice as a Case Study
por: Murphy, Aisling, et al.
Publicado: (2022)

The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA
por: Gherghescu, Ioana, et al.
Publicado: (2020)

Availability of Authorizations from EMA and FDA for Age-Appropriate Medicines Contained in the WHO Essential Medicines List for Children 2019
por: delMoral-Sanchez, Jose-Manuel, et al.
Publicado: (2020)

EMA advice on COVID-19 vaccine-related thrombosis with thrombocytopenia
Publicado: (2021)

Lutathera(®): The First FDA- and EMA-Approved Radiopharmaceutical for Peptide Receptor Radionuclide Therapy
por: Hennrich, Ute, et al.
Publicado: (2019)

Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study
por: Hwang, Thomas J, et al.
Publicado: (2020)

Expanded Access as a source of real‐world data: An overview of FDA and EMA approvals
por: Polak, Tobias B., et al.
Publicado: (2020)

Overview of the Side-Effects of FDA- and/or EMA-Approved Targeted Therapies for the Treatment of Hematological Malignancies
por: Constantinescu, Catalin, et al.
Publicado: (2020)

FDA and EMA Approvals of New Breast Cancer Drugs—A Comparative Regulatory Analysis
por: Leo, Chandra P., et al.
Publicado: (2020)

First COVID-19 Vaccines Receiving the US FDA and EMA Emergency Use Authorization
por: Fortner, Andra, et al.
Publicado: (2021)

Adaptive clinical trial designs for European marketing authorization: a survey of scientific advice letters from the European Medicines Agency
por: Elsäßer, Amelie, et al.
Publicado: (2014)

Elements of Regulatory Dissonance: Examining FDA and EMA Product Labeling of New Vaccines (2006–2018)
por: Seo, Yurim, et al.
Publicado: (2020)

Evaluation of the draft guidelines proposed by EMA and FDA for the clinical diagnosis of acute uncomplicated cystitis in women
por: Alidjanov, Jakhongir F., et al.
Publicado: (2019)

EMA and FDA psychiatric drug trial guidelines: assessment of guideline development and trial design recommendations
por: Boesen, Kim, et al.
Publicado: (2021)

Necessity of strengthening the current clinical regulatory for companion diagnostics: An institutional comparison of the FDA, EMA, and MFDS
por: Kang, Su Lim, et al.
Publicado: (2023)

EMA issues recommendations on impurities in medicines
Publicado: (2020)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

The impact of FDA and EMA regulatory decision-making process on the access to CFTR modulators for the treatment of cystic fibrosis
por: Costa, Enrico, et al.
Publicado: (2022)

Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Parallel Scientific Computing and Optimization
por: Henty, David, et al.
Publicado: (2008)

No two classes of biosimilars: Urgent advice to the US Congress and the FDA
por: Niazi, Sarfaraz K.
Publicado: (2022)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

A Critical Overview of FDA and EMA Statistical Methods to Compare In Vitro Drug Dissolution Profiles of Pharmaceutical Products
por: Muselík, Jan, et al.
Publicado: (2021)

Postmarketing studies for novel drugs approved by both the FDA and EMA between 2005 and 2010: a cross-sectional study
por: Zeitoun, Jean-David, et al.
Publicado: (2017)

A Disability Bioethics Reading of the FDA and EMA Evaluations on the Marketing Authorisation of Growth Hormone for Idiopathic Short Stature Children
por: Murano, Maria Cristina
Publicado: (2020)

Process of drug registration in Israel: the correlation between the number of discussions within the Ministry of Health and postapproval variations by EMA and/or FDA
por: Hiayev, Stephany, et al.
Publicado: (2023)

EMA : escala multidimensional de asertividad : manual /
por: Flores Galaz, Mirta Margarita
Publicado: (2004)

Ema, la cautiva
por: Aira, César, 1949-

Entering First-in-Human Clinical Study With a Single-Strain Live Biotherapeutic Product: Input and Feedback Gained From the EMA and the FDA
por: Paquet, Jeanne-Céleste, et al.
Publicado: (2021)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Science and Scientific Advice in a Time of Crisis
por: Petersen, Ole H
Publicado: (2020)

Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020
por: Choi, Hyeyoung, et al.
Publicado: (2022)

The Use of Remote Monitoring Technologies: A Review of Recent Regulatory Scientific Advices, Qualification Opinions, and Qualification Advices Issued by the European Medicines Agency
por: Dekker, Marieke J. H. J., et al.
Publicado: (2021)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Keyboard and display for EMAS system
por: Ollenhauer, F
Publicado: (1974)

Assuring Access to Safe Medicines in Pregnancy and Breastfeeding
por: Nooney, Janet, et al.
Publicado: (2021)

Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency
por: Collignon, Olivier, et al.
Publicado: (2018)

Evaluation of Companion Diagnostics in Scientific Advice and Drug Marketing Authorization Applications by the European Medicines Agency
por: Maliepaard, Marc, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kvfgkas3duhgslr0edhlbg1d0v